---
title: Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine
  kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma
date: '2025-02-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39921522/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20250209170437&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: In this phase-2a study (NCT01994382), patients aged ≥18 years with relapsed/refractory
  peripheral T-cell lymphoma (PTCL; angioimmunoblastic T-cell lymphoma/T follicular
  helper [AITL/TFH], n = 29); PTCL-not otherwise specified [NOS], n = 11; and Other,
  n = 25) received 30 mg oral cerdulatinib, a reversible dual inhibitor of spleen
  tyrosine kinase and Janus kinase, twice daily in 28-day cycles until disease progression
  or unacceptable toxicity. Overall response rate (ORR) was 36.2% (12 ...
disable_comments: true
---
In this phase-2a study (NCT01994382), patients aged ≥18 years with relapsed/refractory peripheral T-cell lymphoma (PTCL; angioimmunoblastic T-cell lymphoma/T follicular helper [AITL/TFH], n = 29); PTCL-not otherwise specified [NOS], n = 11; and Other, n = 25) received 30 mg oral cerdulatinib, a reversible dual inhibitor of spleen tyrosine kinase and Janus kinase, twice daily in 28-day cycles until disease progression or unacceptable toxicity. Overall response rate (ORR) was 36.2% (12 ...